pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Cardiology · news · pharmadog
← back to Cardiology
News · Cardiology
332
stories
9d
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
biospace
9d
STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
stat
9d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
9d
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
9d
STAT+: Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care
stat
9d
Opinion: Climate change is making people with chronic illness even sicker
stat
9d
STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
stat
9d
Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths
stat
10d
Vaderis hauls in $152M to test an AKT-targeting drug
biopharma dive
10d
IRBs have a problem. Can North Star’s nonprofit model save it?
stat
10d
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
stat
11d
BMS picks Texas for new $2.3B manufacturing campus
biospace
11d
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
stat
11d
STAT+: FDA panel to weigh Grail’s Galleri test
stat
11d
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
11d
Tenax shares nosedive as heart failure drug fails in Phase 3
biospace
11d
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
stat
11d
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study
stat
11d
BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication
biospace
11d
Catheter Introducer Correction: Abiomed and Oscor Issue Correction for Catheter Introducer
fda medwatch
14d
Is the biotech capital of the world moving?
stat
14d
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
14d
STAT+: He grew up near Boston, went to Harvard, and worked at MIT. Why did he found his startup in California?
stat
15d
STAT+: FDA approves Replimune melanoma drug previously rejected twice
stat
15d
STAT+: Study reveals new role for tau, a top target for Alzheimer’s drug development
stat
15d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
15d
STAT+: Two FDA approvals — a new drug and a new vaccine
stat
15d
Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
stat
15d
LifeMine raises $263M in mission to improve organ transplant aftercare
biospace
15d
STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment
stat
← prev
page 2 of 12
next →
